DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Temporarily Closed to Accrual: 40, 46.
For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.
Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.
Research committees
Treatment
Eligibility Criteria Expand/Collapse
S1609 cohorts are opened and closed at irregular intervals. Consult the SWOG S1609 Accrual report at: http://www.swogstat.org/accrual/dart.pdf for Cohort status and planned Cohort Closures PRIOR TO CONSENTING PATIENTS to S1609.
Publication Information Expand/Collapse
2024
PMid: PMID38358334
PMid: PMID37882676 | PMC number: PMC10842092
Correlation Between Tumor Size Change and Outcome in a Rare Cancer Immunotherapy Basket Trial
PMid: PMID38243705 | PMC number: PMC11077308
2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Bronchoalveolar Carcinoma of the Lung (Cohort 12)
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The non-epithelial ovarian tumor cohort #13
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The clear cell gynecologic cancer cohorts #42, 45, 46
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The small cell carcinoma of the ovary, hypercalcemic type cohort #49
Clinical outcomes and translational analysis of DART S1609: the thyroid cancer cohort; PD-1+ PD-L1+ TIL correlated with favorable survival
2022
PMid: PMID34716198 | PMC number: PMC8776596
2021
PMid: PMID33882143 | PMC number: PMC8606104
2020
PMid: PMID31969335 | PMC number: PMC7231627
PMid: PMID33215052 | PMC number: PMC7670562
PMid: PMID32414761